Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
Status:
Completed
Trial end date:
2021-03-04
Target enrollment:
Participant gender:
Summary
The SchistoSAM study is an open label, two-arm, individually-randomized controlled trial with
a non-inferiority design, conducted in northern Senegal.
The study aims at determining if the efficacy of one and of repeated courses of
artesunate-mefloquine (AM) is respectively similar to or higher than that of a standard
praziquantel (PZQ) treatment. Secondly, the study will assess if novel DNA- and antigen-based
diagnostics are more accurate than microscopy in assessing antischistosomal treatment
response.
Phase:
Phase 3
Details
Lead Sponsor:
Institute of Tropical Medicine, Belgium
Collaborator:
Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation (IRESSEF)